The ESMO Advanced Course on Defining Endocrine Sensitivity & Optimising Treatment Strategies in HR+/HER2− mBC Patients 2026, organized by the European Society for Medical Oncology (ESMO), will take place on November 25, 2026, in Barcelona, Spain.

The course will focus on the increasingly complex management of hormone receptor-positive, HER2-negative metastatic breast cancer, particularly how clinicians define endocrine sensitivity and resistance and use these distinctions to guide treatment decisions.

The programme is designed to support evidence-based therapeutic selection and sequencing as treatment options for HR+/HER2− metastatic disease continue to expand, with emphasis on integrating clinical and molecular information into individualized patient management.